Skip to main content
English
Català
Español
Company
Overview & History
Team
Join Oryzon
Epigenetics
Histone Code Hypothesis
Modulator Enzymes
LSD1 & Disease
Technology Platforms
Scientific Publications by Oryzon
Therapeutic Programs
Strategy
LSD1 & Cancer
Oryzon's Pipeline
Collaborative Research
Collaborative Projects
For Patient
Patient Information
Shareholders and Investors
Investor Information and News
Share Information
Events & Presentations
Financial Information & Downloads
Analyst Coverage
Corporate Governance
Corporate Social Responsibility
News & Press Releases
Contact
General Contact
Investor Contact
Email Alerts
News
Archive
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
News & Press Releases
31 May 2017
Oryzon Genomics to Participate in a Panel at the JMP Securities Life Sciences Conference and Present at the Jefferies 2017 Global Health Conference
16 May 2017
Oryzon announces appointment of new Chief Medical Officer and expansion of its Medical Department
9 May 2017
ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2017
5 May 2017
Dr. Carlos Buesa, CEO and Founder of Oryzon, received the award for the Best Entrepreneur
24 April 2017
ORYZON Announces New Grant from Alzheimer’s Drug Discovery Foundation (ADDF) to develop a companion marker for its ORY-2001 epigenetic drug
3 April 2017
ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases
31 March 2017
Oryzon Raises €18 Million through a Private Placement with US and European Investors
20 March 2017
Oryzon to Present at the Sachs Associates 2nd Annual Neuroscience BioPartnering & Investment Forum
15 March 2017
ORYZON to Present at the 11th Annual BIO-Europe Spring International Partnering Conference
27 February 2017
ORYZON presented new preclinical data of ORY-2001 therapeutic activity in Multiple Sclerosis at ACTRIMS-2017
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »